Milton-based CCL has teamed up with Prostatype Genomics.
Two targets have been identified.
Industry veterans have backed the company.
The company is already with pharma and universities.
It is plotting a Series A funding round.
The immuno-oncology and inflammatory disease specialist is targeting activated fibroblast populations.
It will lead to new treatments for disease.
The oversubscribed round was co-led by Omega Funds and TCG X.
It includes pharma leaders and patient advocates.
Connect: Health Tech suggest how cultural, financial and geographical challenges can be overcome.
It is designed to help life science companies roll out solutions more quickly.
It brings the company greater immunology and rare disease expertise.
Daniel Gleghorn and colleagues at Cambridge University Hospitals won the award from Benson Viscometers.
The Babraham Research Campus company will develop tissue-targeted oligonucleotide therapeutics.
The company was created to speed up the development of therapeutics.